| Medullary carcinoma of thyroid
Caprelsa vs Retevmo
Side-by-side clinical, coverage, and cost comparison for medullary carcinoma of thyroid.Deep comparison between: Caprelsa vs Retevmo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRetevmo has a higher rate of injection site reactions vs Caprelsa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Retevmo but not Caprelsa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Caprelsa
Retevmo
At A Glance
Oral
Daily
Tyrosine kinase inhibitor
Oral
Twice daily
RET kinase inhibitor
Indications
- Medullary carcinoma of thyroid
- Non-Small Cell Lung Carcinoma
- Medullary carcinoma of thyroid
- Thyroid carcinoma
Dosing
Medullary carcinoma of thyroid 300 mg orally once daily until disease progression or unacceptable toxicity; reduce to 200 mg then 100 mg for Grade 3+ toxicities or QTcF >500 ms; reduce starting dose to 200 mg in moderate renal impairment (CrCl >=30 mL/min); not recommended in moderate or severe hepatic impairment.
Non-Small Cell Lung Carcinoma, Medullary carcinoma of thyroid, Thyroid carcinoma Adults and adolescents >= 12 years: 120 mg orally twice daily (< 50 kg) or 160 mg orally twice daily (>= 50 kg); pediatric patients 2 to < 12 years: 40 mg three times daily to 160 mg twice daily orally based on body surface area; administered until disease progression or unacceptable toxicity.
Contraindications
- Congenital long QT syndrome
—
Adverse Reactions
Most common (>20%) Diarrhea/colitis, rash, acneiform dermatitis, hypertension, nausea, headache, upper respiratory tract infection, decreased appetite, abdominal pain, fatigue
Serious QT prolongation and Torsades de pointes, severe skin reactions, interstitial lung disease, ischemic cerebrovascular events, hemorrhage, heart failure, hypothyroidism, hypertension, reversible posterior leukoencephalopathy syndrome, renal failure, embryo-fetal toxicity, osteonecrosis
Postmarketing Arterial aneurysms/dissections/rupture, osteonecrosis, impaired wound healing
Most common (>=25%) edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, constipation, rash, nausea, headache
Serious hepatotoxicity, interstitial lung disease/pneumonitis, hypertension, QT interval prolongation, hemorrhagic events, hypersensitivity, tumor lysis syndrome, impaired wound healing, hypothyroidism, slipped capital femoral epiphysis in adolescents
Postmarketing Stevens-Johnson Syndrome
Pharmacology
Vandetanib is a multi-targeted tyrosine kinase inhibitor that blocks the activity of EGFR and VEGFR families, RET, BRK, TIE2, and members of the EPH receptor and Src kinase families, thereby inhibiting tumor cell proliferation, angiogenesis, tumor vessel permeability, and metastasis.
Selpercatinib is a kinase inhibitor that selectively inhibits wild-type RET and multiple mutated RET isoforms (including gene fusions and activating point mutations) as well as VEGFR1 and VEGFR3, and at clinically achievable concentrations also inhibits FGFR1, 2, and 3, blocking constitutive RET signaling that acts as an oncogenic driver promoting tumor cell proliferation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Caprelsa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (10/12) · Qty limit (11/12)
No coverage data available for Retevmo.
UnitedHealthcare
Caprelsa
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (4/8) · Qty limit (2/8)
Retevmo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Caprelsa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Retevmo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$50/momo
Caprelsa Co Pay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Retevmo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CaprelsaView full Caprelsa profile
RetevmoView full Retevmo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.